Ashis Kumar Dey

1) Cadila Healthcare Q2FY21 net profit jumped over four-fold to Rs 473.4 crore. The company had posted a net profit of Rs 107.2 crore for the same period of last FY. Consolidated total revenue from operations of the company stood at Rs 3,820 crore. The net debt as on 30th Sept, 2020 stood at Rs 4,031 crore against Rs 6,740. crore as on 31st Mar, 2020. 2) India October Manufacturing PMI reported 12 years high. Germany reported 8-month high October PMI. US reported PMI for manufacturing registered 59.3% in October, the highest level since September 2018. Expect positive for metal stocks ahead of strong demand.  #MOMarketUpdates #MotilalOswal #IndianStockMarket #stockinvesting #Cadila #steel #sensex #nifty #stocktips

The Pharma stocks are positive due to multiple approvals of US FDA for different medicines. The companies are also manufacturing the drugs for the primary treatment of Covid-19. Dr Reddy's Laboratories reclaimed the tag of being the second most valuable listed pharmaceutical company. Sun Pharma is the most valued listed company of India with the market cap of Rs 1.26lakh cr. With a favourable ruling in the appeals court, the odds of launching gVascepa also rise considerably. Bristol Myers Squibb had inked a patent settlement with Dr. Reddy’s Laboratories, allowing the Indian generics company to start with a “volume-limited” launch sometime after March 2022. The exact date of the rollout, and amount of generic Revlimid Dr. Reddy’s will be allowed to sell, are confidential. But on January 31, 2026, the company will have a license to sell its generic Revlimid with no limits. #MOMarketUpdates #IndianStockMarket #MotilalOswal #NiftyPharma #NSE #BSE #Recommendation #Stocktip #Stockrecommendation